Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.
复制标题
DOI：
10.1186/1756-8722-1-18
复制
发表时间：
2008-10-17
影响因子：
28.5
通讯作者：
Patel T
中科院分区：
文献类型：
--
作者：
So BJ;Bekaii-Saab T;Bloomston MA;Patel T
肝细胞癌是罕见的，但在美国的患病率正在增加。最近的研究表明，索拉非尼，一种多激酶抑制剂，可以减少这种癌症患者的肿瘤进展。然而，尚未观察到完全缓解。我们报告一例78岁的患者患有不可切除的转移性肝细胞癌，经索拉非尼治疗6个月后获得了快速和完全的临床反应。停止治疗后6个月内未发现疾病复发的证据。
Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.
登录
查看更多内容
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
11.2
作者：
Wilhelm, SM;Carter, C;Trail, PA
通讯作者：
Trail, PA
影响因子：
254.7
作者：
Parkin, DM;Bray, F;Pisani, P
通讯作者：
Pisani, P
影响因子：
3
作者：
Chang, Yong S.;Adnane, Jalila;Wilhelm, Scott
通讯作者：
Wilhelm, Scott